Zimmer Biomet Holdings, Inc. (ZBH)
| Market Cap | 17.90B |
| Revenue (ttm) | 7.70B |
| Net Income (ttm) | 913.40M |
| Shares Out | 197.84M |
| EPS (ttm) | 4.51 |
| PE Ratio | 20.07 |
| Forward PE | 11.00 |
| Dividend | $0.96 (1.06%) |
| Ex-Dividend Date | Mar 31, 2025 |
| Volume | 7,058,349 |
| Open | 99.01 |
| Previous Close | 102.38 |
| Day's Range | 89.98 - 99.01 |
| 52-Week Range | 89.92 - 122.25 |
| Beta | 0.78 |
| Analysts | Buy |
| Price Target | 124.15 (+37.21%) |
| Earnings Date | May 5, 2025 |
About ZBH
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open hear... [Read more]
Financial Performance
In 2024, Zimmer Biomet Holdings's revenue was $7.68 billion, an increase of 3.85% compared to the previous year's $7.39 billion. Earnings were $903.80 million, a decrease of -11.74%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for ZBH stock is "Buy." The 12-month stock price forecast is $124.15, which is an increase of 37.21% from the latest price.
News
Hip Implant Maker Zimmer Biomet Cuts Annual Profit Forecast On Paragon 28 Deal
Zimmer Biomet Holdings, Inc ZBH reported first-quarter adjusted EPS of $1.81, down from $1.94 a year ago, beating the Street estimates of $1.77.
Zimmer Biomet Holdings, Inc. (ZBH) Q1 2025 Earnings Call Transcript
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants David DeMartino - SVP, IR Ivan Tornos - President & CEO Suketu Upadhyay - CFO & EV...
Zimmer Biomet lowers 2025 profit forecast on acquisition costs, tariff uncertainty
Zimmer Biomet Holdings on Monday lowered its full-year adjusted profit forecast, as the medical device maker anticipates a hit from its recent acquisition of Paragon 28 , currency volatility, and prop...
Zimmer Biomet Announces First Quarter 2025 Financial Results
First quarter net sales of $1.909 billion increased 1.1% and 2.3% on a constant currency1 basis First quarter diluted earnings per share were $0.91; adjusted1 diluted earnings per share were $1.81 Com...
Zimmer Biomet Completes Acquisition of Paragon 28
Transaction Further Strengthens Company's Position in High-Growth Foot and Ankle Segment WARSAW, Ind., April 21, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. ("Zimmer Biomet"; NYSE and SIX: ZBH),...
Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2025 Financial Results
WARSAW, Ind. , April 10, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its first quarter earnings conference call will be webcast on Monday, May 5, 2025, at 8:3...
PARAGON 28 INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Paragon 28, Inc. - FNA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Paragon 28, Inc....
Zimmer Biomet Receives CE Mark Approval for RibFix Advantage® Fixation System
Expanding Thoracic Portfolio WARSAW, Ind., and ZUG, Switzerland , April 1, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today announc...
Paragon 28 Announces Expiration of HSR Act Waiting Period for Pending Acquisition by Zimmer Biomet Under HSR Act
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announc...
Zimmer Biomet Highlights Diverse Portfolio of Orthopedic & Musculoskeletal Innovations at AAOS 2025 Annual Meeting
Booth Spotlights Comprehensive Hip Portfolio, Newly Launched Knee and Upper Extremities Reconstructive Technologies, Including Recently Cleared Persona® Revision SoluTion™ Femur, and Debut of ZBX™ Amb...
Zimmer Biomet Receives FDA Clearance for Persona® Revision SoluTion™ Femur
A Revision Knee Implant Alternative for Patients with Metal Sensitivities WARSAW, Ind., March 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology lead...
Zimmer Biomet Names Kristen Cardillo as Senior Vice President, Chief Communications Officer
WARSAW, Ind., March 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kristen Cardillo as Senior Vice Pre...
Zimmer Biomet to Present at the 27th Annual Barclays Healthcare Conference
WARSAW, Ind. , Feb. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the 27th Annual Ba...
Zimmer Biomet Appoints Jehanzeb Noor as Senior Vice President, Chief Strategy, Innovation and Business Development Officer
WARSAW, Ind. , Feb. 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Jehanzeb Noor is joining the Company as Senior V...
Zimmer Biomet Launches You'll Be Back Campaign with Chief Movement Officer Arnold Schwarzenegger
Schwarzenegger Invites People Living with Joint Pain to Join New Online Community, Share Their Stories and Connect with a Qualified Physician WARSAW, Ind. , Feb. 26, 2025 /PRNewswire/ -- Zimmer Biomet...
Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2025
WARSAW, Ind. , Feb. 26, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment ...
Zimmer Biomet Announces Upcoming Changes to Company's Board of Directors
WARSAW, Ind. , Feb. 25, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced upcoming changes to the Company's Board of Directors,...
Zimmer Biomet: Adding To The Growth Profile
Zimmer Biomet shares at $105 reveal value at 13 times adjusted earnings, as the company continues to grow despite a GLP-1 drug overhang. The 2015 Zimmer Biomet merger hasn't been fully delivered, but ...
Why Is Zimmer Biomet Stock Trading Lower On Thursday?
On Thursday, Zimmer Biomet Holdings, Inc ZBH reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating the Street estimates of $2.30.
Zimmer Biomet Holdings, Inc. (ZBH) Q4 2024 Earnings Call Transcript
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q4 2024 Earnings Conference Call February 6, 2025 8:30 AM ET Company Participants David DeMartino - Senior Vice President-Investor Relations Ivan Tornos - Pres...
Zimmer Biomet forecasts 2025 profit below estimates
Medical device maker Zimmer Biomet Holdings forecast full-year adjusted profit below Wall Street estimates on Thursday, as it anticipates a hit from a strong dollar.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Paragon 28, Inc.
NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Paragon 28, Inc. (NYSE: FNA) and its board of directors concerning the proposed acquisi...
Zimmer Biomet to buy Paragon 28 for $1.1 billion
Zimmer Biomet said on Tuesday it would acquire medical device company Paragon 28 for about $1.1 billion.
Zimmer Biomet Announces Webcast and Conference Call of Fourth Quarter 2024 Financial Results
WARSAW, Ind., Jan. 16, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its fourth quarter earnings conference call will be webcast on Thursday, February 6, 2025 a...
Zimmer Biomet: Back On Offense With Strong Cash Flow Outlook
Zimmer Biomet Holdings (ZBH) is expanding its product portfolio and improving cash flow, positioning it for long-term profitability and financial health. ZBH is undervalued compared to peers, with sig...